- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05877235
Serum Concentration of Endogenous Estrogens and Sirtuin-1 After Administration of Atorvastatin and Quercetin:
May 17, 2023 updated by: ANTONIO DE PADUA MANSUR, InCor Heart Institute
Serum Concentration of Endogenous Estrogens and Sirtuin-1 in Postmenopausal Women With Atherosclerotic Coronary Heart Disease After Administration of Atorvastatin and Supplementation With Quercetin: a Randomized Study
Chronic coronary syndrome (CCS) is the leading cause of death in women in the most developed regions of Brazil.
The primary etiopathogenic mechanism is the process of atherosclerosis.
A healthy diet rich in fruits and vegetables is associated with a lower incidence of CCS.
The higher consumption of these foods promotes greater availability of phenolic compounds, and the higher intake of these compounds is one of the main hypotheses for vascular health.
Quercetin, a phenolic compound, is the most abundant natural antioxidant belonging to the group of flavonoids.
Quercetin improves lipoprotein metabolism, has an antioxidant capacity, produces vasodilating substances in the vascular endothelium, and reduces platelet aggregability.
Likewise, statins are medications known to reduce cardiovascular events in women with CCS by reducing serum LDL-cholesterol levels and, to a lesser extent, by possible pleiotropic effects.
In turn, SIRT1 is one of the 7 classes of proteins.
It mediates various metabolic pathways in response to nutritional stimuli, particularly for caloric restriction and phenolic compounds, as well as coordinating the production and secretion of important hormones.
However, the impact of quercetin supplementation and statin administration on serum endogenous estrogen levels is unknown
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The main objective of this study is to investigate the influence of atorvastatin and of quercetin in the serum concentrations of estradiol and estrone after the administration of atorvastatin and supplementation with quercetin.
This is a randomized, double-blind, placebo-controlled, 60-day study in 60 postmenopausal women with CAD, divided into three groups of 20 women each: Group 1 - quercetin (500 mg/day); Group 2 - atorvastatin (80 mg/day); Group 3 - control (placebo).
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
São Paulo
-
Sao Paulo, São Paulo, Brazil, 05403900
- Recruiting
- INCOR- Heart Institute
-
Contact:
- Antonio de Pádua Mansur, PHD
- Phone Number: 11 26615387
- Email: apmansur@yahoo.com
-
Principal Investigator:
- Antonio P Mansur, PhD
-
Sub-Investigator:
- Nathalia FO Faria
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Postmenopausal women;
- Diagnosed coronary artery disease;
- Stable coronary disease;
Exclusion Criteria:
- hypo or hyperthyroidism,
- rheumatic disease,
- use of alcohol,
- hepatic failure,
- renal failure
- hormone replacement therapy
- use of insulin
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Quercetin
Trans-quercetin, 1000 mg daily for 60 days
|
Trans-quercetin, 1000 mg daily for 60 days
|
Experimental: Atorvastatin
Atorvastatin, 80mg daily for 60 days.
|
Trans-quercetin, 1000 mg daily for 60 days
|
Placebo Comparator: Control
Starch, 1000mg daily for 60 days.
|
Starch, 1000 mg daily for 60 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estradiol
Time Frame: 60 days
|
serum concentrations
|
60 days
|
Estrone
Time Frame: 60 days
|
serum concentrations
|
60 days
|
Sirtuin-1
Time Frame: 60 days
|
Serum concentrations and gene expression
|
60 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiometabolic risk factors
Time Frame: 60 days
|
Lipid and glucometabolic profiles
|
60 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 3, 2021
Primary Completion (Estimated)
December 23, 2023
Study Completion (Estimated)
June 23, 2024
Study Registration Dates
First Submitted
May 17, 2023
First Submitted That Met QC Criteria
May 17, 2023
First Posted (Actual)
May 26, 2023
Study Record Updates
Last Update Posted (Actual)
May 26, 2023
Last Update Submitted That Met QC Criteria
May 17, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 64417922.0.0000.0068
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Quercetin
-
Factors Group of Nutritional Companies Inc.Completed
-
Kanuni Sultan Suleyman Training and Research HospitalOrbiteratec (funding)Completed
-
Temple UniversityNational Center for Complementary and Integrative Health (NCCIH); Quercegen...RecruitingChronic Obstructive Pulmonary Disease | Emphysema | Chronic Bronchitis With Airway ObstructionUnited States
-
University of Alabama at BirminghamNational Institutes of Health (NIH)CompletedCystic FibrosisUnited States
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompleted
-
Brigham and Women's HospitalNational Institute on Aging (NIA)CompletedStroke | Problem of AgingUnited States
-
Azienda di Servizi alla Persona di PaviaCompletedSleep | Body Composition | Chronic Fatigue Syndrome | Physical PerformanceItaly
-
Children's Hospital Medical Center, CincinnatiActive, not recruitingFanconi Anemia | Squamous Cell CarcinomaUnited States
-
Children's Hospital Medical Center, CincinnatiFood and Drug Administration (FDA)Completed
-
Mashhad University of Medical SciencesCompletedChemotherapy Induced Oral MucositisIran, Islamic Republic of